Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Pixantrone (Primary) ; Bendamustine; Rituximab
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2014 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
- 17 Dec 2011 New trial record